Previous Close | 2.4100 |
Open | 2.4900 |
Bid | 0.0000 x 1000 |
Ask | 0.0000 x 1800 |
Day's Range | 2.4500 - 2.7400 |
52 Week Range | 0.7000 - 3.1100 |
Volume | |
Avg. Volume | 1,024,479 |
Market Cap | 206.202M |
Beta (5Y Monthly) | 1.43 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2500 |
Earnings Date | Nov 09, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for APLT
Regulatory Submissions and Phase 3 Trials in Focus
Regulatory submissions on track for govorestat (AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023 Two Upcoming Phase 3 Trial Readouts, with ARISE-HF Trial of AT-001 (caficrestat) in Diabetic Cardiomyopathy on track for data readout in 4Q 2023 and INSPIRE Trial of AT-007 trial in Sorbitol Dehydrogenase (SORD) Deficiency in 1Q 2024 NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developin
Key Insights Institutions' substantial holdings in Applied Therapeutics implies that they have significant influence...